Victoza (Liraglutide 6 MG/mL)

• Victoza (liraglutide) is a glucagon−like peptide−1 (GLP−1) receptor agonist used:
• along with diet and exercise to help improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
• to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. 

 Limitations of Use: This therapeutic drug is not for the treatment of type 1 diabetes mellitus. It should not be coadministered with other liraglutide-containing products.

Recommended Dosage: 

Adult Patients: The recommended starting dosage is 0.6 mg administered subcutaneously once daily for one week. The 0.6 mg once-daily dosage is intended to reduce gastrointestinal symptoms during initial titration and is not effective for glycemic control in adults. After one week at the 0.6 mg once daily dosage, increase the dosage to 1.2 mg injected subcutaneously once daily. If additional glycemic control is required, the dosage can be increased to the maximum recommended dosage of 1.8 mg administered subcutaneously once daily after at least 1 week of treatment with the 1.2 mg once daily dosage.

Pediatric Patients Aged 10 Years and Older: The recommended starting dosage is 0.6 mg administered subcutaneously once daily. If additional glycemic control is required, the dosage can be increased in 0.6 mg increments after at least 1 week on the current dosage. The maximum recommended dosage is 1.8 mg administered subcutaneously once daily.

• Treatment with Liraglutide may increase the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is not recommended for patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Symptoms such as a lump in the neck, hoarseness, or trouble swallowing should be promptly reported to a healthcare provider.
• There have been reports of acute pancreatitis in patients using Liraglutide 6 mg/mL injection. Patients should be monitored for signs of pancreatitis, such as severe abdominal pain that may radiate to the back, and discontinue the medication if pancreatitis is suspected.
• When used with other medications that lower blood sugar, such as insulin or sulfonylureas, this medicine can increase the risk of hypoglycemia (low blood sugar). Patients should be educated on the signs and symptoms of hypoglycemia and how to manage it.
• This therapeutic drug may cause nausea, vomiting, or diarrhea, which can lead to dehydration and worsening of kidney function. Patients with renal impairment should be closely monitored, and fluid intake should be maintained to prevent dehydration.
• Serious allergic reactions, including anaphylaxis and angioedema, have been reported with this treatment. Symptoms such as rash, itching, difficulty breathing, or swelling of the face, lips, tongue, or throat require immediate medical attention.
• Victoza should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. There are no adequate and well-controlled studies of Victoza in pregnant women, and it should be used with caution.

Indian Pharma Network can source the VICTOZA (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Victoza®?

Liraglutide is a Generic Name for the trade name drug Victoza®.

What is the Manufacturer’s Name of Victoza®?

Victoza® is manufactured by Novo Nordisk.

Is Victoza® approved by the FDA?

Yes, Victoza® is approved by the FDA. Date of first approval: January 25, 2010.

What is the dosage and form of Victoza® supplied?

Victoza® is supplied as injections: 6 mg/mL solution in a pre-filled, single-patient-use pen that delivers doses of 0.6 mg, 1.2 mg, or 1.8 mg. 

What are the most common side effects of Victoza®? 

The most common side effects of Victoza® are diarrhea, vomiting, decreased appetite, dyspepsia, nausea, and constipation.

How much does Victoza® cost in India?

Prices may fluctuate over time due to market dynamics and regulatory changes. To obtain accurate and up-to-date information on the cost of Victoza in India, it is recommended to Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Victoza®?

Victoza® should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F) and protected from light.

Is it safe to buy Victoza® online in India?

Yes, one can buy Victoza online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in the country. We can help facilitate the supply of Victoza® through legal channels.